- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Propanc Biopharma, Inc.: Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal | 2 | GlobeNewswire (USA) | ||
| 04.12. | Propanc Biopharma, Inc.: Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs | 146 | GlobeNewswire (Europe) | MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for chronic diseases... ► Artikel lesen | |
| 01.12. | Propanc Biopharma: Aktie steigt nach Patentanträgen für resistente Krebstherapien | 2 | Investing.com Deutsch | ||
| 01.12. | Propanc Biopharma, Inc.: Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis | 1 | GlobeNewswire (USA) | ||
| 17.11. | Propanc Biopharma, Inc. GAAP EPS of $0.39 | 1 | Seeking Alpha | ||
| PROPANC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 17.11. | Propanc Biopharma, Inc.: Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results | 286 | GlobeNewswire (Europe) | MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for recurrent and... ► Artikel lesen | |
| 14.11. | Propanc Biopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Propanc Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11. | Propanc Biopharma secures up to $100 million private placement | 1 | Seeking Alpha | ||
| 10.11. | Propanc Biopharma secures $1 million initial investment from Hexstone | 3 | Investing.com | ||
| 10.11. | Propanc Biopharma secures up to $100 million investment from Hexstone | 1 | Investing.com | ||
| 10.11. | Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline | 1 | GlobeNewswire (USA) | ||
| 04.11. | Propanc Biopharma plant Übernahme von Unternehmen für digitale Vermögenswerte | 8 | Investing.com Deutsch | ||
| 04.11. | Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) | 3 | GlobeNewswire (USA) | ||
| 15.10. | Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital | 2 | Seeking Alpha | ||
| 15.10. | Propanc Biopharma, Inc.: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital | 279 | GlobeNewswire (Europe) | MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100... ► Artikel lesen | |
| 14.10. | Propanc Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Propanc Biopharma meldet nach NASDAQ-Listing finanzielle Trendwende | 1 | Investing.com Deutsch | ||
| 07.10. | Propanc Biopharma reports major financial transformation after Nasdaq listing | 1 | Investing.com | ||
| 07.10. | Propanc Biopharma reports major financial turnaround after Nasdaq uplisting | 1 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,388 | +3,10 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| AMGEN | 279,55 | -0,50 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| BIOFRONTERA | 2,430 | +4,29 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,000 | -3,69 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,430 | -0,69 % | Bionxt Solutions Inc: Bionxt Solutions talks up sublingual thin-film product | ||
| NOVONESIS | 53,90 | +0,97 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| TEMPUS AI | 55,50 | -2,63 % | How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up | ||
| GENMAB | 284,40 | +1,97 % | Genmab A/S: Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period | Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| EXACT SCIENCES | 86,01 | -0,74 % | Aktien New York: Euphorie über Nvidia-Zahlen hält nicht lange an | NEW YORK (dpa-AFX) - Die Freude über einen überraschend starken Quartalsbericht des KI-Chip-Spezialisten Nvidia ist am Donnerstag an den US-Börsen im Verlauf verflogen. Die fest in den Handelstag gestarteten... ► Artikel lesen | |
| TME PHARMA | 0,059 | -12,20 % | TME Pharma announces receipt of agreements in principle to extend certain bond agreements | TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage... ► Artikel lesen | |
| CYTODYN | 0,210 | 0,00 % | CytoDyn Inc.: December 2025 Letter to Shareholders | VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,245 | -3,52 % | Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? | ||
| IMMUNIC | 0,501 | +0,91 % | EQS-News: Immunic AG: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
26.11.2025 / 12:30 CET/CEST
The... ► Artikel lesen |
PROPANC BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,586 Euro und damit -11,24 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROPANC BIOPHARMA INC finden Sie auf Wallstreet Online.